Navigation Links
Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
Date:4/22/2009

- Company to Highlight Data for its Two Newest Urological Products -

CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a global leader in the development and distribution of pharmaceuticals, announced today that management will host and webcast a meeting for the investment community at the American Urological Association (AUA) Annual Meeting taking place in Chicago, Illinois, April 25-30, 2009.

The company will be hosting the meeting to review new data on its two newest brands, RAPAFLO (silodosin) and GELNIQUE (oxybutynin chloride) Gel 10%, including:

  • Two post-hoc analyses of Phase 3 trials for RAPAFLO(TM) (silodosin): On efficacy, specifically for irritative and obstructive symptoms; and retrograde ejaculation - a harmless side effect of treatment - as an indicator of treatment efficacy. Reviewed by Herbert Lepor, M.D., Department of Urology, New York University School of Medicine, NY
  • The efficacy, safety and tolerability of GELNIQUE(TM) (oxybutynin chloride) Gel 10% versus placebo from Phase 3 trials. Reviewed by Roger R. Dmochowski, M.D., Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

The event will be held on Monday, April 27, 2009, from 3:00 p.m. to 5:00 p.m. (CDT) at The Hyatt McCormick in Conference Center Room 12D, adjacent to the McCormick Center, where the AUA meeting is being held. To participate in the event in person, please RSVP to Scott Anderson, Watson Pharmaceuticals, by Friday, April 24, via e-mail, scott.anderson@watson.com, or phone, (951) 493-9684.

The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Web site at http://ir.watson.com. Pre-registration is not required to view the webcast. An archived version will be available for 30 days after the live presentation and can be accessed at the same location.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology (Medical).

In the U.S., the Watson portfolio includes RAPAFLO, GELNIQUE, TRELSTAR(R) LA and TRELSTAR(R) Depot, Ferrlecit(R), INFeD(R), and Oxytrol(R). In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.

For press releases and other company information, visit the Watson website at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including GELNIQUE and RAPAFLO; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by the Company and the ability to successfully enforce such rights against third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOG)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
2. Mark G. Watson Named Executive Director of Radiological Society of North America
3. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
4. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
5. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
6. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
7. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
9. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
10. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
11. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Halfway through its partnership with First 5 LA, Western University of Health ... children 5 years old and younger and treatment services to more than 9,100 of ... years to Western University of Health Sciences, UCLA and USC, beginning March 1, 2013, ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... 02, 2016 , ... Center for Autism and Related Disorders (CARD) Portland today ... spectrum disorder (ASD) and other developmental disabilities. The group, which is being launched with ... caregivers the opportunity to share stories and advice, seek help, and continue their education ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading provider of ... Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep track of ... new version is a faster and a more efficient product, allowing batch processing ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... , , ... in 2015, and it is expected to grow at a CAGR of ... to witness faster growth during the forecast period, a CAGR of 8.8% ...
(Date:12/2/2016)... Dec. 2, 2016 In the first ever ... from those derived from C. sativa, the Hebrew University ... di Napoli Federico II , the Universita` del Piemonte ... comprehensive, critical, integrated and unified inventory of phytocannabinoids of ... focuses on the remarkable chemical and structural diversity of ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
Breaking Medicine Technology: